Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma

Hiroaki Tanioka, Akihito Tsuji, Sojiro Morita, Tadashi Horimi, Masahiro Takamatsu, Tetsuhiko Shirasaka, Takaaki Mizushima, Koji Ochi, Katsuyuki Kiura, Mitsune Tanimoto

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: In this study we evaluated the efficacy and toxicities of combination chemotherapy consisting of continuous 5-fluorouracil (5-FU) infusion and low-dose cisplatin infusion (low-dose FP therapy) in the treatment of advanced hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight patients with advanced HCC in whom local treatment was not indicated were enrolled. The low-dose FP therapy consisted of 5-FU (170mg/m2/day on days 1 to 7/week, continuous infusion) and cisplatin (3mg/m2/day in 100ml normal saline, infusion more than 30 minutes, on days 1 to 5/week). The patients were treated for 4 consecutive weeks with a subsequent one-week rest period. Results: Thirty-seven of the 38 patients (97%) completed this therapy. A partial response was obtained in 18 (47%), no change in 10 and progressive disease in 9. The time to progression was 211 days. The most common toxicity was nausea/vomiting (13.2%). Conclusion: Low-dose FP therapy has a substantial effect on low-grade toxicity in long-term treatment. Low-dose FP therapy is useful for the treatment of advanced HCC.

Original languageEnglish
Pages (from-to)1891-1897
Number of pages7
JournalAnticancer Research
Volume23
Issue number2 C
Publication statusPublished - Mar 2003

Fingerprint

Combination Drug Therapy
Fluorouracil
Cisplatin
Hepatocellular Carcinoma
Therapeutics
Nausea
Vomiting

Keywords

  • 5-fluorouracil
  • Biochemical modulation
  • Chemotherapy
  • Cisplatin
  • Combination
  • Hepatocellular carcinoma
  • Serum concentration

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tanioka, H., Tsuji, A., Morita, S., Horimi, T., Takamatsu, M., Shirasaka, T., ... Tanimoto, M. (2003). Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Research, 23(2 C), 1891-1897.

Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. / Tanioka, Hiroaki; Tsuji, Akihito; Morita, Sojiro; Horimi, Tadashi; Takamatsu, Masahiro; Shirasaka, Tetsuhiko; Mizushima, Takaaki; Ochi, Koji; Kiura, Katsuyuki; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 23, No. 2 C, 03.2003, p. 1891-1897.

Research output: Contribution to journalArticle

Tanioka, H, Tsuji, A, Morita, S, Horimi, T, Takamatsu, M, Shirasaka, T, Mizushima, T, Ochi, K, Kiura, K & Tanimoto, M 2003, 'Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma', Anticancer Research, vol. 23, no. 2 C, pp. 1891-1897.
Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Research. 2003 Mar;23(2 C):1891-1897.
Tanioka, Hiroaki ; Tsuji, Akihito ; Morita, Sojiro ; Horimi, Tadashi ; Takamatsu, Masahiro ; Shirasaka, Tetsuhiko ; Mizushima, Takaaki ; Ochi, Koji ; Kiura, Katsuyuki ; Tanimoto, Mitsune. / Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. In: Anticancer Research. 2003 ; Vol. 23, No. 2 C. pp. 1891-1897.
@article{1cbe466d0d324761b63e524e8fa833bd,
title = "Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma",
abstract = "Background: In this study we evaluated the efficacy and toxicities of combination chemotherapy consisting of continuous 5-fluorouracil (5-FU) infusion and low-dose cisplatin infusion (low-dose FP therapy) in the treatment of advanced hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight patients with advanced HCC in whom local treatment was not indicated were enrolled. The low-dose FP therapy consisted of 5-FU (170mg/m2/day on days 1 to 7/week, continuous infusion) and cisplatin (3mg/m2/day in 100ml normal saline, infusion more than 30 minutes, on days 1 to 5/week). The patients were treated for 4 consecutive weeks with a subsequent one-week rest period. Results: Thirty-seven of the 38 patients (97{\%}) completed this therapy. A partial response was obtained in 18 (47{\%}), no change in 10 and progressive disease in 9. The time to progression was 211 days. The most common toxicity was nausea/vomiting (13.2{\%}). Conclusion: Low-dose FP therapy has a substantial effect on low-grade toxicity in long-term treatment. Low-dose FP therapy is useful for the treatment of advanced HCC.",
keywords = "5-fluorouracil, Biochemical modulation, Chemotherapy, Cisplatin, Combination, Hepatocellular carcinoma, Serum concentration",
author = "Hiroaki Tanioka and Akihito Tsuji and Sojiro Morita and Tadashi Horimi and Masahiro Takamatsu and Tetsuhiko Shirasaka and Takaaki Mizushima and Koji Ochi and Katsuyuki Kiura and Mitsune Tanimoto",
year = "2003",
month = "3",
language = "English",
volume = "23",
pages = "1891--1897",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 C",

}

TY - JOUR

T1 - Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma

AU - Tanioka, Hiroaki

AU - Tsuji, Akihito

AU - Morita, Sojiro

AU - Horimi, Tadashi

AU - Takamatsu, Masahiro

AU - Shirasaka, Tetsuhiko

AU - Mizushima, Takaaki

AU - Ochi, Koji

AU - Kiura, Katsuyuki

AU - Tanimoto, Mitsune

PY - 2003/3

Y1 - 2003/3

N2 - Background: In this study we evaluated the efficacy and toxicities of combination chemotherapy consisting of continuous 5-fluorouracil (5-FU) infusion and low-dose cisplatin infusion (low-dose FP therapy) in the treatment of advanced hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight patients with advanced HCC in whom local treatment was not indicated were enrolled. The low-dose FP therapy consisted of 5-FU (170mg/m2/day on days 1 to 7/week, continuous infusion) and cisplatin (3mg/m2/day in 100ml normal saline, infusion more than 30 minutes, on days 1 to 5/week). The patients were treated for 4 consecutive weeks with a subsequent one-week rest period. Results: Thirty-seven of the 38 patients (97%) completed this therapy. A partial response was obtained in 18 (47%), no change in 10 and progressive disease in 9. The time to progression was 211 days. The most common toxicity was nausea/vomiting (13.2%). Conclusion: Low-dose FP therapy has a substantial effect on low-grade toxicity in long-term treatment. Low-dose FP therapy is useful for the treatment of advanced HCC.

AB - Background: In this study we evaluated the efficacy and toxicities of combination chemotherapy consisting of continuous 5-fluorouracil (5-FU) infusion and low-dose cisplatin infusion (low-dose FP therapy) in the treatment of advanced hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight patients with advanced HCC in whom local treatment was not indicated were enrolled. The low-dose FP therapy consisted of 5-FU (170mg/m2/day on days 1 to 7/week, continuous infusion) and cisplatin (3mg/m2/day in 100ml normal saline, infusion more than 30 minutes, on days 1 to 5/week). The patients were treated for 4 consecutive weeks with a subsequent one-week rest period. Results: Thirty-seven of the 38 patients (97%) completed this therapy. A partial response was obtained in 18 (47%), no change in 10 and progressive disease in 9. The time to progression was 211 days. The most common toxicity was nausea/vomiting (13.2%). Conclusion: Low-dose FP therapy has a substantial effect on low-grade toxicity in long-term treatment. Low-dose FP therapy is useful for the treatment of advanced HCC.

KW - 5-fluorouracil

KW - Biochemical modulation

KW - Chemotherapy

KW - Cisplatin

KW - Combination

KW - Hepatocellular carcinoma

KW - Serum concentration

UR - http://www.scopus.com/inward/record.url?scp=12444293395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444293395&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1891

EP - 1897

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -